Logo

AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment due to Alzheimer Disease

Share this
AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment due to Alzheimer Disease

AgeneBio Reports Completion of Patient Enrollment in P-IIB HOPE4MCI Trial for AGB101 to Treat Amnestic Mild Cognitive Impairment due to Alzheimer Disease

Shots:

  • The company has completed the enrollment in the P-IIB HOPE4MCI trial evaluating the efficacy of AGB101 vs PBO in 164 patients to treat amnestic mild cognitive impairment due to AD across 23 sites in the US and Canada
  • The HOPE4MCI study followed an earlier study that showed a reduction in hippocampal overactivity and improvement in episodic memory. The HOPE4MCI study will evaluate cognitive and functional efficacy as measured by CDR-SB- MMSE- FAQ
  • The HOPE4MCI trial also includes a sub-study of brain PET imaging to measures neurodegeneration. The results of the study are expected in Nov’2022

  Ref: PRNewswire | Image: Pharmaceutical Report

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions